Retina Synthesis: Recent Episodes
Retina Synthesis
Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.
In this episode, we discuss the use of handheld ERG in the evaluating eye with diabetic retinopathy. ERG is a powerful predictive tool in assessing diabetic retinopathy. Our guest is Dr. Raj Maturi of the Midwest Eye Institute and Adjunct Associate Professor of Ophthalmology, at the Indiana University School of Medicine.
In this episode, we discuss the long term results of faricimab therapy of neovascular AMD with Dr. Carl Danzig of Fort Lauderdale, Florida and Affiliate Assistant Professor at the Charles Schmidt School of Medicine at Florida Atlantic University.
In this episode, we discuss 5 year results of the GALE study which demonstrated that earlier treatment with pegcetacoplan of geographic atrophy preserves more retinal tissue with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Assistant Professor Ophthalmology, Roski Eye Institute, Keck School of Medicine of USC.
In this episode, we discuss the importance of early recognition of PCV, diagnostic techniques, and therapeutic approaches with Professor Jay Chhablani of the University of Pittsburgh.
In this episode, we review the evidence regarding the effectiveness of AREDS vitamin supplementation in affecting the growth of geographic atrophy in age related macular degeneration.
In this episode, we discuss the promising results of intravitreal gene therapy for neovascular AMD with 4D-150 with Dr. Arshad Khanani of Sierra Eye Associates and Clinical Professor of Ophthalmology at the University of Nevada Medical School, Reno.
In this episode, we discuss the latest developments in the use of artificial intelligence in home OCT for management of neovascular AMD with Professor Anat Loewenstein of Tel Aviv Medical Center and President, Israeli Ophthalmology Society.
We discuss long term results of faricimab treatment of DME, with the first author of the Ophthalmology article on the results of Rhone-X trial, Dr. Veeral Sheth, Director of Clinical Research at University Retina in Chicago.
In our latest episode we discuss the results of a novel approach to the treatment of geographic atrophy using Xelafaslatide a Fas inhibitor with Dr. David Zacks, Professor of Ophthalmology at the Kellogg Eye Center at the University of Michigan.
In our latest episode, we discuss the use of inhibitors of IL-6 in the treatment of retinal disease with Dr. Steven M. Yeh, Stanley M. Truhlsen, Jr. , Chair of Ophthalmology a the University of Nebraska.
In this episode, we discuss the use of aflibercept 8mg for the management of retinal vein occlusion and the results of the QUASAR study with Dr. Sunir Garg, Co Director of Retina Research at the Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
In this episode we discuss the results of a phase 2 trial using subcutaneous elamipretide for the treatment of geographic atrophy with Dr. Mark Barakat.
In this episode, we discuss the 3 year results of the Phase 2 trial of the Adverum intravitreal gene therapy with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Professor Ophthalmology, Keck School of Medicine of USC.
In this episode we discuss the impressive Phase 4 results of the Belvedere Trial for treatment of neovascular AMD with Dr. Michael Klufas of Wills Eye Hospital.
In our latest episode with the discuss the promising results of a Phase I clinical trial looking at kamuvudine 8 an inflammasome inhibitor in the treatment of geographic atrophy with Dr. Jayakrishna Ambati, Guerry Professor of Ophthalmology at the University of Virginia School of Medicine.
In this episode, we discuss real world treatment of proliferative diabetic retinopathy using data from the Vestrum data base; with Dr. Adrienne Scott, Fred M. Leader Family Retina Professor of the Wilmer Eye Institute and Johns Hopkins University School of Medicine.
In this episode, we discuss the pathbreaking use of an encapsulated cell therapy that produces CNTF for the successful treatment of MacTel with Roger Goldberg, MD, from Walnut Creek, CA.
In our latest update, we discuss strategies for developing a teleretinology network with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.
In our latest update we discuss the prevention and treatment of endophthalmitis with one of the world's leading authorities, Dr. Harry Flynn , holder of the J. Donald M. Gass Distinguished Chair In Ophthalmology at the Bascom Palmer Eye Institute.
We discuss early studies of ophthalmic artery angioplasty in cases of advanced geographic atrophy with Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute.
In our latest episode, we discuss the results of the PRIMA retinal implant in treating eyes with center involved geographic atrophy as presented in a recent New England Journal of Medicine article. 85% of eyes had meaningful improvement in vision at one year with Dr. Daniel Palanker, Professor of Ophthalmology and Electrical Engineering, Stanford University.
In this episode, In our latest episode, we discuss the results of a randomized trial comparing the Iluvien sustained release steroid implant to aflibercept in the treatment of diabetic macular edema with Dr. Michael Singer, Clinical Professor, University of Texas Health Sciences Center, San Antonio.
We discuss the diagnosis and management of central serous chorioretinopathy with photodynamic therapy with Dr. Andrew Lotery, Professor of Ophthalmology, University of Southhampton, United Kingdom.
In this episode, we discuss the use of low dose cryogenic application for anesthesia prior to intravitreal injection with Dr. Michael Singer, Adjunct Professor University of Texas Health Science Center, San Antonio.
In our latest update, we discuss current treatment of retinopathy of prematurity as well as new developments in disease prevention with Dr. Darius Moshfeghi, Professor of Ophthalmology, Stanford University, Director, Retina Division, Byers Eye Institute.
In this update, we review the TKI program of Eyepoint Pharmaceuticals with Dr. Jay Duker, President and CEO.
We discuss a study that showed that an artificial intelligence powered system can detect clinically significant fluid as well as experienced observers using the Notal Home OCT with Dr. Ted Leng, Professor of Ophthalmology, Byers Eye Institute, Stanford University.
We discuss studies documenting the undertreatment of diabetic macular edema and possible strategies for alleviating it with Dr. Matthew Starr, Assistant Professor, Mayo Clinic, Rochester, Minnesota.
In this episode, we discuss promising results of gene therapy, administered suprachoroidally, for the treatment of nonproliferation diabetic retinopathy without macular edema with Charles Wykoff, MD, Ph.D., Retina Consultants of Houston.
We discuss promising Phase 2 results from Nanoscope regarding the use of optogenetics for treatment of retinal degenerations with Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital.
We discuss the early results of the use of artificial intelligence in the management of macular disorders with Dr. Pearse Keane, the world's first Professor of Artificial Medical Intelligence, University College London, Moorfields Eye Hospital.
We discuss with Dr. Rajesh C. Rao, Leonard Miller Professor of Ophthalmology, Kellogg Eye Center, University of Michigan, the results of a Phase I trial exploring the use of stem cells injected subretinally in eyes with geographic atrophy. The results are promising.
We discuss the early results of gene therapy of neovascular AMD by intravitreal administration of the vector with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.
We discuss the long term results of the Truckee Study, a stage 4 clinical trial in the treatment of neovascular AMD with faricimab with Dr. Arshad Khanani from Sierra Eye Associates, Reno, Nevada.
We discuss the use of a tyrosinase kinase inhibitor, EY-1901, for the treatment of diabetic macular edema with Dr. Yasha Modi, New York University, and Manhattan Eye Ear and Throat Hospital, New York.
We discuss early results from the study of photobiomodulation for the treatment of dry AMD with Dr. David Boyer, Adjunct Professor of Clinical Ophthalmology, Keck School of Medicine of USC, Roski Eye Institute.
We review long term results from the PHOTON Study with Eric Schneider, MD, Tennessee Retina, Nashville, TM.
We review the latest results from the Regenexbio sub retinal gene therapy program with Robert Avery MD, California Retina Consultants, Santa Barbara, CA
We discuss whether pegcetacoplan therapy of geography atrophy affects the progression of dry AMD with Paul Hahn MD PhD of PH Retina, Nanuet, New York.
We discuss the observation that resolution of retinal fluid at one month in eyes with nAMD treated with aflibercept 8mg may herald longer duration treatment intervals at week 96 with Michael Stewart,, MD, Knights Templar Professor of Ophthalmology, Mayo Clinic, Jacksonville, Florida.
We discuss the current state of the Good Days charitable foundation with Dr. Michael Lai, MD. PhD, Retina Group of Washington, Assistant Clinical Professor, Georgetown University School of Medicine
We discuss the long term results of the Oaks, Derby, and GALE studies looking at the benefit of early treatment of geographic atrophy in AMD with Dr. Roger Goldberg of Walnut Creek, California.
We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine
We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.
We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates
We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.
We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas
We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.
We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.
We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.
We discuss the occurrence of retinal vasculitis following pegcetcoplan therapy of geographic atrophy with Dr. Andrew Witkin of the New England Eye Center, Tufts University School of Medicine
We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.
We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California
We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.
We discuss the feasibility of using home OCT vs. a treat and extend approach in a clinical trial of faricimab in neovascular AMD with Dr. Kevin Blinder of the Retina Institute in Saint Louis, Mo and Profesor of Ophthalmology at Washington University School of Medicine.
We discuss the characteristics of eyes with the best visual outcomes in the Davio trial of TKI EY-1901 with Dr. Philip Storey of the Austin Retina Associates, Austin, Texas.
We discuss a post-hoc study comparing the efficacy of Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) with Paul Hahn, MD, PhD, of NJ Retina.
We discuss a comparative trial of preventive therapy for non-proliferative retinopathy vs. ad hoc treatment of disease complications with Dr. Hani Salehi-Had of Retina Associates of Southern California, Huntington Beach, California.
We discuss the latest information on phase 2 trials of gene therapy for x-linked retinitis pigmentosa with Dr. Nadia Waheed, Chief Medical Officer of Beacon Therapeutics and Associate Professor of Ophthalmology at the New England Eye Center, Tufts University School of Medicine.
We discuss the use of optogenetics for the treatment of inherited retinal degenerations with Dr. Jose Sahel, Chairman and Distinguished Professor of Ophthalmology at the University of Pittsburgh School of Medicine.
We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical College
We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.
We review novel approaches for the treatment of intermediate AMD, with Dr. Barry Kuppermann, Director Gavin Herbert Eye Institute, Chairman Department of Ophthalmology, University of California Irvine, Steinert Endowed Chair.
In our latest update, we discuss safety issues associated with retinal gene therapy with Professor Glenn Yiu of the University of California School of Medicine.
We discuss the use of a novel oral agent for the treatment of diabetic retinopathy with David R. Lally, MD, Director of Research, New England Retina Consultants, Springfield, MA
We discuss intravitreal gene therapy with a new agent, 4D-150 with Veeral Sheth, MD, MBA Assistant Clinical Professor of Ophthalmology University of Illinois at Chicago.
We discuss the use of optogenetics in the treatment of retinal degenerations with Dr. Michael Singer, Adjunct Professor of Ophthalmology, University of Texas Health Science Center, San Antonio.
We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.
We discuss the use of blockade of VEGF C and D in the treatment of neovascular AMD with Dr. Dante Pieramici, California Retina Research Foundation, California Retina Consultants.
We discuss the use of a novel treatment approach, senolytic therapy, for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Professor, USC Roski Eye Institute.
We discuss the use of the PDS in the treatment of diabetic retinopathy and diabetic macular edema with Professor Carl Regillo of the Wills Eye Hospital.
Dr. Eugene de Juan, winner of this year's ASRS Pyron Award, joins us to discuss his career highlights. Dr. de Juan is CEO of Forsight Labs and Professor of Ophthalmology, University of California, San Francisco.
In our latest update, We discuss the use of surgical sub retinal gene therapy for neovascular AMD with RGX-314. Our guest Dr. Courtney Crawford, Ft. Worth, Texas.
We discuss the use of an improved implantable telescope as a low vision aid in patients with macular disease with Dr. David Almeida, Erie Retina Research.
We discuss the prevention of vision loss in the Gather 2 trial of IZERVAY with Dr. Carl Danzig of the Rand Eye Institute, Pompano Beach, Florida
We discuss a 30-Month Outcome with Pegcetacoplan for the Treatment of Geographic Atrophy with Nathan Steinle MD, California Retina Consultants, Santa Barbara, California.
We discuss the latest information on Safety & Efficacy in Clinic and Clinical Trials with Cedric Francois, MD, PhD.
We discuss the latest information on the use of faricimab in neovascular AMD with Dr. Yasha Modi, Associate Professor of Ophthalmology, NYU Langone Medical Center.
We discuss the use of high dose aflibercept for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor, Roski Eye Institute of USC.
We discuss the latest information on the use of pegcetacoplan for geographic atrophy in AMD with Dr. Dilsher Dhoot, California Retinal Consultants.
We discuss the use of a novel drug (tyrosine kinase inhibitor) and novel delivery system (hydrogel) for the treatment of neovascular AMD with Dr. Peter Kaiser of the Cleveland Clinic.
We discuss the use of biosimilar drugs for retinal diseases with Dr. Arghavan Almony, author of definitive monograph of these agents.
In our latest update,we discuss the relative drying effects of farcimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.
In our latest update, we discuss the use of artificial intelligence in the management of geographic atrophy with Professor Pearse Keane, Moorfields Eye Hospital, London.
In our latest update, we discuss the use of molecular techniques in the management of uveal melanoma with Dr. William Harbour, Professor and Chair, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.
We discuss the results of clinical trials studying the use of faricimab in the treatment of retinal venous occlusion with Dr. Ramin Tadayoni, Professor of Ophthalmology University of Paris.
We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute
We the discuss the use of wide field OCT angiography in the management of diabetic retinopathy, retinal vein occlusion, and pediatric retinal disease with Dr. Amir Kashani, Associate Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine
We review the use of anti-VEGF therapy for retinopathy of prematurity and in particular, the results of a clinical trial employing aflibercept with Dr. Darius Moshfeghi, Professor of Ophthalmology, Director of the Retina Service, Byers Eye Institute, Stanford University School of Medicine.
We discuss the use of home OCT and artificial intelligence in the management of anti-VEGF therapy of neovascular AMD with Dr. Anat Loewenstein, Director, Department of Ophthalmology, Tel Aviv Medical Center, Israel.
We discuss the use of suprachoroidal triamcinolone for the treatment of macular edema with Dr. Steven Yeh, Truhlsen Chair of Ophthalmology, University of Nebraska School of Medicine.
We discuss the use of the port delivery system for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, Associate Clinical Professor, University of Nevada School of Medicine, Reno.
We discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD with Dr. Mark Barakat, Assistant Clinical Professor of Ophthalmology, University of Arizona School of Medicine-Phoenix.
We discuss the use of microperimetry to assess treatment effects of anti-complement therapy (Apellis) of geographic atrophy with Dr. Nadia Waheed, Associate Professor of Ophthalmology, New England Eye Center, Tufts University School of Medicine.
We discuss the results of the RGX-314 study of subretinal gene therapy for neovascular AMD with Dr. Allen Ho, Professor of Ophthalmology, Wills Eye Hospital.
In our latest update, We discuss the results of a one year Phase I trial exploring the use of a tyrosinase inhibitor in an hydrogel implant for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology, USC Roski Eye Institute.
We discuss long term results of fixed dose anti-VEGF therapy for neovascular AMD with Dr. Ivan Suner, Retina Associates of Florida, Tampa, Florida.
We discuss the use of corticosteroids, in particular, the dexamethasone implant in the management of diabetic macular edema with Dr. Kevin Blinder, Professor of Clinical Ophthalmology at Washington University School of Medicine, The Retina Institute.
Thomas Albini, MD, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute provides a comprehensive review of the etiology, diagnostic evaluation and treatment of retinal vasculitis.
We discuss the latest developments in diagnostic evaluation and treatment of eyes with central serous chorioretinopathy. with Roger Goldberg, MD, Bay Area Retina Associates, Walnut Creek, CA
Dr. Roger Goldberg from Bay Area Retina Associates, Walnut Creek, CA discusses the latest data regarding the use of faricimab in diabetic macular edema and neovascular AMD.
We discuss various strategies for treatment pauses in management of neovascular AMD, differences between bevacizumab and aflibercept in patients who can be successfully paused, and intra ocular biomarkers that may identify eyes in which treatment may be successful paused with Dr. Akrit Sodhi, Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine, Wilmer Eye Institute.
We review the current status of gene therapy for inherited retinal disorders, discussing preoperative evaluation, surgery, and follow up with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute.
We discuss the use of a suprachoroidal delivery system for delivery of tryrosinase kinase inhibitor for the treatment of neovascular AMD with Dr. Thomas Ciulla, Chief Development Officer, Chief Medical Officer, Clearside Biomedical.
We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.
We discuss the use of intravitreal avacincaptad peg for the treatment of geographic atrophy in two randomized trials, Gather 1 and Gather 2 with Dr. Arshad Khanani, Sierra Eye Associates, Reno Nevada and Associate Clinical Professor University of Nevada Reno.
We discuss the role that en-face optical coherence tomography (OCT) can play in understanding the evolution of intermediate AMD and geographic atrophy with Dr. Philip Rosenfeld, Professor of Ophthalmology, Bascom Palmer Eye Institute and the University of Miami Miller School of Medicine.
We review the 24 month results of the Derby and Oaks trials, with emphasis on the safety of pegcetcoplan with Caroline Baumal, MD, Professor of Ophthalmology Tufts University School of Medicine and the New England Eye Center.
Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia at Augusta University discusses the value of ultra wide field imaging in assessing diabetic retinopathy worsening over time.
Dr. Michael Elman of Elman Retina Group, Baltimore, Maryland, presents 10 year data demonstrating that Preferential Hyperacuity Perimetry (the Foresee Device) is a valuable tool in early detection of neovascular AMD.
Dr. Susanna Park reviews current therapy of retinal branch and central vein occlusion and discusses a Phase I trial (the TRUST study) investigating the use of intravitreal autologous stem cells as a possible treatment for central vein occlusion.
Dr. Susanna Park, Professor of Ophthalmology, Roth Endowed Chair in Visual Science at the University of California, Davis
We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.
We review lesion progression in the eighteen month data with Roger Goldberg, MD, MBA of Bay Area Retina Associates, Walnut Creek, California.
We discuss the role that clinicians can play in fostering innovation in the retinal pharmacotherapy space with Dr. Eliot Lazar.
We discuss the 12 month results of the Phase I Davio Trial of an innovative TKI agent for the sustained treatment of neovascular AMD with Dr. Rishi Singh, Professor of Ophthalmology, Cole Eye Insitute, President, Cleveland Cllinic-Martin Hospital, Stuart, Florida.
We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.
We discuss the role of IOP pressure elevation following intravitreal anti-VEGF therapy with Parnian Arjmand, MD, MSC, FCSRS of the Toronto Retina Institute.
We discuss real world experience about faricimab with Dr. Carl Danzig of Pompano Beach, Florida.
We discuss new treatment options and clinical trials for radiation retinopathy with Prithvi Mruthyunjaya MD Professor of Ophthalmology, Stanford Medical School, Director of Ocular Oncology, Byers Eye Institute.
We discuss new developments in gene therapy for inherited retinal diseases with Sue Washer, President and CEO of AGTC.
We discuss a novel strategy using RNA anti sense technology for treating geographic atrophy with Dr. Nik London, San Diego, California.
We discuss the 18 month results of the Derby and Oaks trials of pegcetacoplan for treatment of geographic atrophy with Roger Goldberg, MD of Walnut Creek, California.
We discuss a new retinal sealant that may replace the need for tamponade with expansile gas or silicone oil with Dr. James Anthony Stefater.
We discuss how new developments in imaging and therapeutics have impacted the treatment of sickle cell retinopathy with Dr. Adrienne Scott, Professor of Ophthalmology at Johns Hopkins and the Wilmer Eye Institute.
We discuss the results of a Phase II clinical trail studying the efficacy of high dose aflibercept (8mg) for treating neovascular AMD with Dr. David Brown of Retina Consultants of Texas in Houston.
We discuss new developments in the diagnosis and therapy of choroidal melanoma with Dr. Paul Finger, Clinical Professor, NYU and Chair, Eye Cancer Foundation.
We discuss the two year results of a Phase I/II trial of a stem cell implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.
We discuss the one year results of the DERBY and OAKs studies treating geographic atrophy with Dr. David Lally, Assistant Professor University of Massachusetts and Tufts University.
We discuss the use of deep learning techniques in the detection and management of macular degeneration with Dr. Pearse Keane, Consultant Moorfields Eye Hospital, Professor of Artificial Medical Intelligence University College London.
In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.
We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.
We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.
We discuss the results of the Kingfisher trail, a study employing broluizumab q4 weeks for the treatment of diabetic macular edema with Dr. Mark Barakat, Assistant Clinical Profess of Ophthalmology, University of Arizona College of Medicine Phoenix.
We examine the role of sub retinal fluid in the treatment of neovascular AMD with Dr. David Sarraf, Professor of Ophthalmology, UCLA Stein Eye Institute.
We discussed and learned with Samarendra Mohanty, PhD: President and Founder of Nanoscope Technologies, about the fascinating science of vision restoration through making bipolar cells light-sensitive and the development program of the intravitreally administered gene therapy vMCO-010c, currently being investigated in a Ph2b trial of patients with retinitis pigmentosa.
We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.
Join these renowned experts for a panel discussion on how to incorporate into clinical practice the latest treatments for neovascular age-related macular degeneration (nAMD). The panelists will also share the latest outcomes data and their clinical experience using these therapies.
We review the current status of the Ocular Therapeutics TKI sustained release delivery system for treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology USC Roski Eye Institute.
We review current status of clinical research on gene therapy for neovascular AMD and diabetic retinopathy with Dr. Allen Ho, Professor of Ophthalmology, Jefferson Medical College and Wills Eye Hospital.
We review long term results of the Port Delivery System for treating neovascular AMD with Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida.
We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.
The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.
We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.
We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo,
Chief of the Retina Service at Wills Eye Hospital
Phase I results of suprachoroidal delivery of a gene vector in treating neovascular AMD are promising. A discussion with Nikolas London, MD from Retina Consultant Group in San Diego CA & Scripps Memorial Hospital La Jolla.
Discussion of variations in injection volume for treatment of nAMD, DME and MERVO with Roger Goldberg, M.D., M.B.A., Bay Area Retina Associates
We examine the role of residual IRF and SRF in visual acuity results in treating nAMD. Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida reviews the results of the Hawk and Harrier trials.
We discuss the use of the newly approved Susvimo system for sustained delivery of ranibizumab in the treatment of neovascular AMD with Carl Regillo, MD, Professor of Ophthalmology Thomas Jefferson University and Director of the Retina Service at the Wills Eye Hospital.
We discuss the pathophysiology and techniques associated with subchoroidal administration of drugs and gene therapy vectors with James Major, MD, Ph.D., Retina Consultants of Texas and Houston Methodist Hospital.
We discuss the newly approved Xipere system for suprachoroidal administration of triamcinolone for treatment of macular edema associated with uveitis with Dr. Steven Yeh
In our latest update, We discuss clinical and business careers with Pravin Dugel MD, President, of Iveric Bio.
We discuss with David Lally, MD Springfield, Ma. Assistant Professor at University of Massachusetts and Tufts the use of elamipretide, a novel agent which acts at the level of the mitochondria in the treatment of geographic atrophy.
We discuss with Dr.Christoper Reimann of the Cincinnati Eye Institute the results of an early phase clinical trial in which stem cell derived retina pigment epithelial cells are injected into the sub retinal space in the maculas of eyes with geographic atrophy.
We discuss the use of suprachoroidal gene therapy for eyes with diabetic retinopathy without macular edema with Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia.
Dr. Yasha Modi, Associate Professor of Ophthalmology at the NYU Langone Medical Center provides an evidence based review of management of retinal venous occlusion.
We discuss the use of a cooling probe as primary anesthesia for intravitreal injection with Ajay Kuriyan, MD, Associate Professor of Ophthalmology, Wills Eye Hospital.
We discuss blockade of complement component C1q as a novel treatment for geographic atrophy with Donald Fong, MD, Vice President Ophthalmology Clinical Development, Annexon.
We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.
We asked Dr. Mohamed Genead, Chief Medical Officer, Nanoscope Therapeutics to discuss and review the latest developments in optogenetic gene therapy for retinal degenerations.
Dr. Robert Avery of California Retina Consultants reviews the latest status of gene therapy for AMD and DR.
Many drugs are currently being investigated in attacking or supplementing the complement cascade for the treatment of geographic atrophy. We review, with the help of Dr. Johanna Seddon, Professor of Ophthalmology, University of Massachusetts Medical Center the basic biology that underlies these treatments, and assess their clinical potential.
We interview Dr. Caroline Baumal, Professor Of Ophthalmology at New England Eye Center and the Tufts University School of Medicine and we review clinical applications and safety results of brolucizumab.
Dr. Linda Lam, Professor of Ophthalmology at the USC Roski Eye Institute talks about augmented reality for low vision and unique surgical applications.
Dr Barone describes the mission of Gemini and discusses recent preliminary data from the ongoing Phase 2a REGATTA study
We knew that anti-VEGF therapy favorably affected the natural history of moderate or severe nonproliferation retinopathy. As a result of DRCR network Protocol W, we now know that careful observation with treatment of complications as they develop produces visual acuity results at 2 years similar to prophylactic therapy.
Dr. Dilsher Dhoot discusses patient outcomes in the PANORAMA trial looking at areas of non perfusion.
Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.
A Real World Clinical Trial Employing AI
Dr. Anat Loewenstein presents data demonstrating the effectiveness of the Notal Home OCT System with artificial intelligence for real world monitoring of eyes undergoing anti-VEGF therapy.
Dr. Usha Chakravarthy, Professor of Ophthalmology, Queen's University Belfast presents characteristics of macular neovascularization at its earliest diagnosis.
Diana Do, MD, Professor of Ophthalmology, Vice Chair Clinical Affairs, Department of Ophthalmology, Stanford University, Byers Eye Institute.
In this episode, Dr. David Boyer discusses a Phase 2 trial studying intravitreal injection of retinal progenitor cells for treatment of eyes with retinitis pigmentosa.
Join us as Dr. Carmen Puliafito joins in a discussion with Carl Regillo, MD, Director of Retina Serivce, Wills Eye Institute on the topic of Phase 3 Results from the Port Delivery System (PDS) Phase 3 Trial.
Join us as Dr. Charles Wykoff dives in a discussion with Arshad Khanani MD, MA in a discussion on Faricimab in the TENAYA and LUCERN Phase 3 nAMD Trials: Interpreting the Results
Dr. Carmen Puliafito interviews Andrew Moshfeghi, MD on a topic: Tyrosine Kinase Inhibitor Delivery by Hydrogel for Treatment of Wet AMD
Join us in a discussion with Dr. Charles Wykoff & Karl Csaky MD, PhD on Faricimab for DME and nAMD. Interpreting the Durability Signals from the Phase 3 Programs.
Join us as Dr. Carmen Puliafito and Charles Wykoff MD, PhD speak about the results. 1 of 3 total parts to "Interpreting Faricimab Phase 3 Data in DME & nAMD"
Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.
Michael Goldstein MD, MM Chief Medical Officer at Ocular Therapeutix also served as Co-Director, Cornea, External Disease and Cataract Service; Refractive Surgery Service; Uveitis & Immunology Service; Assistant Professor, Tufts University School of Medicine.
Spotlight on David Zacks, M.D., Ph.D. Co-Founder and Chief Science Officer at ONL Therapeutics.
Focus on Kourous Rezaei Chief Medical Officer at IVERIC bio in a discussion with Charles Wykoff.
Join Dr. Carmen Puliafito and Adam Rogers, MD in a discussion on Hemera Biosciences's approach in treating Geographic atrophy.
Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute joins Dr. Charles Wykoff and Dr. Carmen Puliafito in a wide ranging discussion on what every clinician needs to know about macular degeneration.
Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute joins Dr. Charles Wykoff and Dr. Carmen Puliafito furthering questions about geographic atrophy and the future of retina imaging.
Join us in a discussion with Jay S. Duker, MD Chief Strategic Scientific Officer of EyePoint Pharmaceuticals. Director of New England Eye Center, Professor and Chair of Ophthalmology at Tufts University School of Medicine with our moderator Dr. Carmen Puliafito.
Thomas Ciulla, vitreoretinal surgeon and current Chief Medical Officer at Clearside Biomedical, discusses his journey through academics, private practice and into the pharmaceutical industry, describing the motivations that have driven his career path choices.
Join us in a discussion with Dr. Karl Csaky CEO of Retina Foundation of the Southwest also Co-Founder of Vinci Pharmaceuticals with our moderator Dr. Carmen Puliafito.
Join Charles C. Wykoff MD, PhD for a conversation with Jason Ehrlich, MD, PhD, Chief Medical Officer, Chief Development Officer at Kodiak Sciences. Jason Ehrlich, ophthalmologist by training discusses insights gleaned along the road of drug development.